Status:
COMPLETED
A Study Evaluating Implementation Strategies for the Delivery of Cabotegravir in Low and High-Volume PrEP Site in the United States
Lead Sponsor:
ViiV Healthcare
Conditions:
HIV Infections
Eligibility:
MALE
18+ years
Phase:
PHASE4
Brief Summary
This is a two-arm study evaluating the impact of two implementation strategy conditions, dynamic implementation and routine implementation on the feasibility of delivering of Cabotegravir PrEP in low ...
Eligibility Criteria
Inclusion
- Participant must be ≥ 18 years of age inclusive, at the time of signing the informed consent.
- No prior history of receiving CAB PrEP
- HIV negative test result at screening
- Capable of giving signed informed consent form
Exclusion
- HIV indeterminate or positive test result during screening and prior to initiation of CAB PrEP
- A participant of concurrent interventional clinical or implementation science study at any time during the study
Key Trial Info
Start Date :
May 18 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 8 2024
Estimated Enrollment :
287 Patients enrolled
Trial Details
Trial ID
NCT05374525
Start Date
May 18 2022
End Date
August 8 2024
Last Update
December 15 2025
Active Locations (17)
Enter a location and click search to find clinical trials sorted by distance.
1
GSK Investigational Site
Los Angeles, California, United States, 90036
2
GSK Investigational Site
San Francisco, California, United States, 94102
3
GSK Investigational Site
Washington D.C., District of Columbia, United States, 20005
4
GSK Investigational Site
Miami, Florida, United States, 33140